142 related articles for article (PubMed ID: 17391728)
1. Expression and clinical role of the bric-a-brac tramtrack broad complex/poxvirus and zinc protein NAC-1 in ovarian carcinoma effusions.
Davidson B; Berner A; Trope' CG; Wang TL; Shih IM
Hum Pathol; 2007 Jul; 38(7):1030-1036. PubMed ID: 17391728
[TBL] [Abstract][Full Text] [Related]
2. Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival.
Davidson B; Trope' CG; Wang TL; Shih IeM
Gynecol Oncol; 2006 Dec; 103(3):814-9. PubMed ID: 16844205
[TBL] [Abstract][Full Text] [Related]
3. Different clinical roles for p21-activated kinase-1 in primary and recurrent ovarian carcinoma.
Davidson B; Shih IeM; Wang TL
Hum Pathol; 2008 Nov; 39(11):1630-6. PubMed ID: 18656238
[TBL] [Abstract][Full Text] [Related]
4. Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma.
Elstrand MB; Kleinberg L; Kohn EC; Tropé CG; Davidson B
Int J Gynecol Pathol; 2009 May; 28(3):211-21. PubMed ID: 19620938
[TBL] [Abstract][Full Text] [Related]
5. Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status.
Bock AJ; Tuft Stavnes H; Kærn J; Berner A; Staff AC; Davidson B
Tumour Biol; 2011 Jun; 32(3):589-96. PubMed ID: 21350924
[TBL] [Abstract][Full Text] [Related]
6. Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients.
Davidson B; Lazarovici P; Ezersky A; Nesland JM; Berner A; Risberg B; Tropé CG; Kristensen GB; Goscinski M; van de Putte G; Reich R
Clin Cancer Res; 2001 Nov; 7(11):3457-64. PubMed ID: 11705863
[TBL] [Abstract][Full Text] [Related]
7. Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion.
Davidson B; Smith Y; Nesland JM; Kærn J; Reich R; Tropè CG
Hum Pathol; 2013 Nov; 44(11):2449-60. PubMed ID: 24011953
[TBL] [Abstract][Full Text] [Related]
8. Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma.
Bunkholt Elstrand M; Dong HP; Ødegaard E; Holth A; Elloul S; Reich R; Tropé CG; Davidson B
Hum Pathol; 2010 Jun; 41(6):794-804. PubMed ID: 20153512
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions.
Davidson B; Reich R; Kopolovic J; Berner A; Nesland JM; Kristensen GB; Tropé CG; Bryne M; Risberg B; van de Putte G; Goldberg I
Clin Exp Metastasis; 2002; 19(2):135-44. PubMed ID: 11964077
[TBL] [Abstract][Full Text] [Related]
10. Kallikrein 4 expression is up-regulated in epithelial ovarian carcinoma cells in effusions.
Davidson B; Xi Z; Klokk TI; Tropé CG; Dørum A; Scheistrøen M; Saatcioglu F
Am J Clin Pathol; 2005 Mar; 123(3):360-8. PubMed ID: 15716231
[TBL] [Abstract][Full Text] [Related]
11. Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance.
Hetland TE; Hellesylt E; Flørenes VA; Tropé C; Davidson B; Kærn J
Hum Pathol; 2011 Jul; 42(7):1019-26. PubMed ID: 21315408
[TBL] [Abstract][Full Text] [Related]
12. HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases.
Hetland TE; Holth A; Kærn J; Flørenes VA; Tropé CG; Davidson B
Virchows Arch; 2012 May; 460(5):505-13. PubMed ID: 22476403
[TBL] [Abstract][Full Text] [Related]
13. HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival.
Stavnes HT; Holth A; Don T; Kærn J; Vaksman O; Reich R; Trope' CG; Davidson B
Gynecol Oncol; 2013 May; 129(2):358-63. PubMed ID: 23438671
[TBL] [Abstract][Full Text] [Related]
14. Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival.
Brenne K; Nymoen DA; Hetland TE; Trope' CG; Davidson B
Hum Pathol; 2012 Apr; 43(4):496-505. PubMed ID: 21855111
[TBL] [Abstract][Full Text] [Related]
15. E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions.
Davidson B; Berner A; Nesland JM; Risberg B; Berner HS; Tropè CG; Kristensen GB; Bryne M; Ann Florenes V
J Pathol; 2000 Dec; 192(4):460-9. PubMed ID: 11113863
[TBL] [Abstract][Full Text] [Related]
16. The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions.
Davidson B; Holth A; Hellesylt E; Tan TZ; Huang RY; Tropé C; Nesland JM; Thiery JP
Hum Pathol; 2015 Jan; 46(1):1-8. PubMed ID: 25455994
[TBL] [Abstract][Full Text] [Related]
17. Expression of cell cycle proteins in ovarian carcinoma cells in serous effusions-biological and prognostic implications.
Davidson B; Risberg B; Berner A; Nesland JM; Tropé CG; Kristensen GB; Bryne M; Goscinski M; van de Putte G; Flørenes VA
Gynecol Oncol; 2001 Nov; 83(2):249-56. PubMed ID: 11606079
[TBL] [Abstract][Full Text] [Related]
18. Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions.
Slipicevic A; Holth A; Hellesylt E; Tropé CG; Davidson B; Flørenes VA
Gynecol Oncol; 2014 Oct; 135(1):118-24. PubMed ID: 25093290
[TBL] [Abstract][Full Text] [Related]
19. Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions.
Elstrand MB; Stavnes HT; Tropé CG; Davidson B
Hum Pathol; 2012 Apr; 43(4):529-35. PubMed ID: 21864883
[TBL] [Abstract][Full Text] [Related]
20. Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance.
Hetland TE; Nymoen DA; Holth A; Brusegard K; Flørenes VA; Kærn J; Tropé CG; Davidson B
Hum Pathol; 2013 May; 44(5):777-85. PubMed ID: 23114921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
